(Q37408128)

20 August 2017

DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine (English)

1 reference

20 August 2017

0 references

5

Dirk Hose

1 reference

20 August 2017

4

Hartmut Goldschmidt

1 reference

20 August 2017

Jerome Moreaux

1

1 reference

20 August 2017

Angelique Bruyer

series ordinal

2

1 reference

20 August 2017

Jean-Luc Veyrune

series ordinal

3

1 reference

20 August 2017

Bernard Klein

series ordinal

6

1 reference

20 August 2017

language of work or name

English

0 references

publication date

13 November 2013

1 reference

British Journal of Haematology

20 August 2017

1 reference

20 August 2017

164

1 reference

20 August 2017

4

1 reference

20 August 2017

613-616

1 reference

Epigenetic modulating agents as a new therapeutic approach in multiple myeloma

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5104837

Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5104837

Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5104837

Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5104837

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5104837

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5104837

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5104837

The potential role of epigenetic therapy in multiple myeloma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5104837

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5104837

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24224771

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/BJH.12660

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

24224771

1 reference